{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:35:55Z","timestamp":1785796555607,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-023-03267-6","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T13:02:17Z","timestamp":1688389337000},"page":"461-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone metastatic cancer of unknown primary at initial presentation"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-0550","authenticated-orcid":false,"given":"Masatake","family":"Matsuoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamasaki","family":"Masanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimasa","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"issue":"7","key":"3267_CR1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.6004\/jnccn.2014.0093","volume":"12","author":"DS Ettinger","year":"2014","unstructured":"Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, et al. Occult primary, version 3.2014. J Natl Compr Canc Netw. 2014;12(7):969\u201374. https:\/\/doi.org\/10.6004\/jnccn.2014.0093.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1 Suppl","key":"3267_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/1097-0142(19950101)75:1+<353::aid-cncr2820751317>3.0.co;2-p","volume":"75","author":"C Muir","year":"1995","unstructured":"Muir C. Cancer of unknown primary site. Cancer. 1995;75(1 Suppl):353\u20136. https:\/\/doi.org\/10.1002\/1097-0142(19950101)75:1+%3c353::aid-cncr2820751317%3e3.0.co;2-p.","journal-title":"Cancer"},{"issue":"6","key":"3267_CR3","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1200\/JCO.1994.12.6.1272","volume":"12","author":"JL Abbruzzese","year":"1994","unstructured":"Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol. 1994;12(6):1272\u201380. https:\/\/doi.org\/10.1200\/JCO.1994.12.6.1272.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3267_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1056\/NEJM199307223290407","volume":"329","author":"JD Hainsworth","year":"1993","unstructured":"Hainsworth JD, Greco FA. Treatment of patients with cancer of an unknown primary site. N Engl J Med. 1993;329(4):257\u201363. https:\/\/doi.org\/10.1056\/NEJM199307223290407.","journal-title":"N Engl J Med"},{"issue":"1","key":"3267_CR5","first-page":"53","volume":"4","author":"JS Nystrom","year":"1977","unstructured":"Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR, Wolf RM. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol. 1977;4(1):53\u20138.","journal-title":"Semin Oncol"},{"issue":"5","key":"3267_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/030089169307900507","volume":"79","author":"JI Mayordomo","year":"1993","unstructured":"Mayordomo JI, Guerra JM, Guijarro C, Garcia-Prats MD, Gomez A, Lopez-Brea M, et al. Neoplasms of unknown primary site: a clinicopathological study of autopsied patients. Tumori. 1993;79(5):321\u20134. https:\/\/doi.org\/10.1177\/030089169307900507.","journal-title":"Tumori"},{"issue":"8","key":"3267_CR7","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.1995.13.8.2094","volume":"13","author":"JL Abbruzzese","year":"1995","unstructured":"Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13(8):2094\u2013103. https:\/\/doi.org\/10.1200\/JCO.1995.13.8.2094.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3267_CR8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cncr.22410","volume":"109","author":"P Seve","year":"2007","unstructured":"Seve P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109(2):292\u20139. https:\/\/doi.org\/10.1002\/cncr.22410.","journal-title":"Cancer"},{"issue":"14","key":"3267_CR9","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1016\/s0959-8049(03)00547-1","volume":"39","author":"N Pavlidis","year":"2003","unstructured":"Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39(14):1990\u20132005. https:\/\/doi.org\/10.1016\/s0959-8049(03)00547-1.","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"3267_CR10","doi-asserted-by":"publisher","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","volume":"26","author":"K Fizazi","year":"2015","unstructured":"Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G, et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v133\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdv305.","journal-title":"Ann Oncol"},{"issue":"8","key":"3267_CR11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/NEJMra1303917","volume":"371","author":"GR Varadhachary","year":"2014","unstructured":"Varadhachary GR, Raber MN. Cancer of unknown primary site. N Engl J Med. 2014;371(8):757\u201365. https:\/\/doi.org\/10.1056\/NEJMra1303917.","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"3267_CR12","doi-asserted-by":"publisher","first-page":"i75","DOI":"10.1093\/annonc\/mdi804","volume":"16","author":"E Briasoulis","year":"2005","unstructured":"Briasoulis E, Tolis C, Bergh J, Pavlidis N, Force EGT. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP). Ann Oncol. 2005;16(Suppl 1):i75\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdi804.","journal-title":"Ann Oncol"},{"issue":"9824","key":"3267_CR13","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","volume":"379","author":"N Pavlidis","year":"2012","unstructured":"Pavlidis N, Pentheroudakis G. Cancer of unknown primary site. Lancet. 2012;379(9824):1428\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(11)61178-1.","journal-title":"Lancet"},{"issue":"10","key":"3267_CR14","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.1158\/1078-0432.CCR-04-2236","volume":"11","author":"JL Dennis","year":"2005","unstructured":"Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, Downie I, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11(10):3766\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2236.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3267_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdv543","volume":"27","author":"HH Yoon","year":"2016","unstructured":"Yoon HH, Foster NR, Meyers JP, Steen PD, Visscher DW, Pillai R, et al. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol. 2016;27(2):339\u201344. https:\/\/doi.org\/10.1093\/annonc\/mdv543.","journal-title":"Ann Oncol"},{"issue":"5","key":"3267_CR16","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/bjc.2013.386","volume":"109","author":"D Urban","year":"2013","unstructured":"Urban D, Rao A, Bressel M, Lawrence YR, Mileshkin L. Cancer of unknown primary: a population-based analysis of temporal change and socioeconomic disparities. Br J Cancer. 2013;109(5):1318\u201324. https:\/\/doi.org\/10.1038\/bjc.2013.386.","journal-title":"Br J Cancer"},{"issue":"1","key":"3267_CR17","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000448431","volume":"105","author":"JY Scoazec","year":"2017","unstructured":"Scoazec JY, Couvelard A, Monges G, Guyetant S, Bisot-Locard S, Parot X, et al. Professional practices and diagnostic issues in neuroendocrine tumour pathology: results of a prospective one-year survey among french pathologists (the PRONET Study). Neuroendocrinology. 2017;105(1):67\u201376. https:\/\/doi.org\/10.1159\/000448431.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"3267_CR18","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/archsurg.2010.10","volume":"145","author":"SC Wang","year":"2010","unstructured":"Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010;145(3):276\u201380. https:\/\/doi.org\/10.1001\/archsurg.2010.10.","journal-title":"Arch Surg"},{"issue":"28","key":"3267_CR19","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","volume":"27","author":"A Rinke","year":"2009","unstructured":"Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27(28):4656\u201363. https:\/\/doi.org\/10.1200\/JCO.2009.22.8510.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3267_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1316158","volume":"371","author":"ME Caplin","year":"2014","unstructured":"Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1316158.","journal-title":"N Engl J Med"},{"key":"3267_CR21","doi-asserted-by":"publisher","unstructured":"Moertel CG, Kvols LK, O'Connell MJ, Rubin J. (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68(2):227\u201332. https:\/\/doi.org\/10.1002\/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i.","DOI":"10.1002\/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i"},{"issue":"8","key":"3267_CR22","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","volume":"81","author":"E Mitry","year":"1999","unstructured":"Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81(8):1351\u20135. https:\/\/doi.org\/10.1038\/sj.bjc.6690325.","journal-title":"Br J Cancer"},{"key":"3267_CR23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1756-0500-5-70","volume":"5","author":"KW Chen","year":"2012","unstructured":"Chen KW, Liu CJ, Lu HJ, Tzeng CH, Liu JH, Chiou TJ, et al. Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study. BMC Res Notes. 2012;5:70. https:\/\/doi.org\/10.1186\/1756-0500-5-70.","journal-title":"BMC Res Notes"},{"issue":"8","key":"3267_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/(sici)1097-0347(199812)20:8<674::aid-hed3>3.0.co;2-h","volume":"20","author":"PJ Colletier","year":"1998","unstructured":"Colletier PJ, Garden AS, Morrison WH, Goepfert H, Geara F, Ang KK. Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: outcomes and patterns of failure. Head Neck. 1998;20(8):674\u201381. https:\/\/doi.org\/10.1002\/(sici)1097-0347(199812)20:8%3c674::aid-hed3%3e3.0.co;2-h.","journal-title":"Head Neck"},{"issue":"6","key":"3267_CR25","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/hed.20581","volume":"29","author":"M Aslani","year":"2007","unstructured":"Aslani M, Sultanem K, Voung T, Hier M, Niazi T, Shenouda G. Metastatic carcinoma to the cervical nodes from an unknown head and neck primary site: Is there a need for neck dissection? Head Neck. 2007;29(6):585\u201390. https:\/\/doi.org\/10.1002\/hed.20581.","journal-title":"Head Neck"},{"issue":"3","key":"3267_CR26","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/1097-0142(19870201)59:3<572::AID-CNCR2820590336>3.0.CO;2-3","volume":"59","author":"A Guarischi","year":"1987","unstructured":"Guarischi A, Keane TJ, Elhakim T. Metastatic inguinal nodes from an unknown primary neoplasm. A review of 56 cases. Cancer. 1987;59(3):572\u20137.","journal-title":"Cancer"},{"issue":"6","key":"3267_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.prro.2013.12.007","volume":"4","author":"K Joseph","year":"2014","unstructured":"Joseph K, Sawyer MB, Amanie J, Jones Thachuthara J, Ghosh S, Tai P. Carcinoma of unknown primary in the inguinal lymph node region of squamous cell origin: a case series. Pract Radiat Oncol. 2014;4(6):404\u20138. https:\/\/doi.org\/10.1016\/j.prro.2013.12.007.","journal-title":"Pract Radiat Oncol"},{"issue":"16","key":"3267_CR28","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","volume":"21","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2013the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150\u20137. https:\/\/doi.org\/10.1200\/JCO.2003.04.105.","journal-title":"J Clin Oncol"},{"issue":"16","key":"3267_CR29","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48(16):3082\u201392. https:\/\/doi.org\/10.1016\/j.ejca.2012.08.002.","journal-title":"Eur J Cancer"},{"key":"3267_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091270","author":"A Argentiero","year":"2019","unstructured":"Argentiero A, Solimando AG, Brunetti O, Calabrese A, Pantano F, Iuliani M, et al. Skeletal metastases of unknown primary: biological landscape and clinical overview. Cancers (Basel). 2019. https:\/\/doi.org\/10.3390\/cancers11091270.","journal-title":"Cancers (Basel)"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03267-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03267-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03267-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T05:24:08Z","timestamp":1706160248000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03267-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["3267"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03267-6","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"10 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IY reports grants from KAKENHI, AMED, and Health, Labour and Welfare Policy Research Grants, research funds from Nihon Medi-Physics, and speaking fees from Chugai Pharmaceutical Co. and AstraZeneca, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}